What is the recommended first‑line treatment and dosing for chloroquine‑resistant malaria in adults and children?

Chloroquine-Resistant Malaria Treatment

For chloroquine-resistant malaria, do not use chloroquine as first-line therapy; instead, use artemisinin-based combination therapies (ACTs) such as artemether-lumefantrine, dihydroartemisinin-piperaquine, or atovaquone-proguanil, with specific dosing based on body weight and age. 1

First-Line Treatment Options for Uncomplicated Chloroquine-Resistant P. falciparum

Adults

Artemether-Lumefantrine (AL) is the most commonly recommended first-line ACT 1, 2:

• Standard weight-based dosing over 3 days
• Take with fatty food to enhance absorption 1

Dihydroartemisinin-Piperaquine (DHA-PPQ) 1:

• Alternative first-line ACT option
• Once-daily dosing for 3 days

Atovaquone-Proguanil (A-P) 1:

• Another first-line option
• 4 tablets daily for 3 days in adults

Children

Same ACT regimens apply, with weight-based dosing 1:

• Artemether-lumefantrine: dose according to weight bands
• DHA-PPQ: weight-based dosing over 3 days
• Atovaquone-proguanil: pediatric formulations available

Alternative Second-Line Options

If ACTs are unavailable or contraindicated, alternative regimens include 3:

Sulfadoxine-Pyrimethamine (Fansidar) 3, 4:

• Demonstrated >90% cure rates in chloroquine-resistant cases 4
• Single-dose administration

Quinine plus Doxycycline 3, 1:

• Adults: Quinine 750 mg (3 tablets) three times daily for 3-7 days PLUS doxycycline 100 mg twice daily for 7 days 1
• Not for use in children <8 years or pregnant women (doxycycline contraindicated) 1

Quinine plus Clindamycin 3, 1:

• Adults: Quinine 750 mg three times daily for 3-7 days PLUS clindamycin 20 mg/kg every 8 hours for 7 days 1
• Safe alternative when doxycycline contraindicated 1

Mefloquine 3, 1:

• Not recommended for P. falciparum from Southeast Asia due to resistance 1
• Contraindicated in patients with neuropsychiatric history 1

Severe/Complicated Malaria (All Ages)

Intravenous Artesunate is the ONLY first-line treatment 1:

• 2.4 mg/kg IV at 0,12, and 24 hours, then daily 1
• Switch to oral ACT once able to tolerate oral medication and parasitemia <1% 1
• Monitor for post-artesunate delayed hemolysis (PADH) 1

Intravenous Quinine (second-line if artesunate unavailable) 1:

• Loading dose: 20 mg salt/kg over 4 hours 1
• Maintenance: 10 mg/kg over 4 hours every 8 hours 1
• Monitor for QT prolongation and hypoglycemia 1

Critical Clinical Monitoring

Assess treatment response at 48-72 hours 3:

• If symptoms persist after 48-72 hours of treatment, switch to second-line therapy immediately 3
• Repeat thick blood smear if symptoms continue beyond 3 days 3
• Alternative therapy required if parasitemia has not diminished markedly 3

Important Caveats

Geographic resistance patterns matter 2:

• Only 3 of 13 non-endemic countries adjust treatment based on expected artemisinin resistance 2
• Southeast Asian P. falciparum shows resistance to multiple agents including mefloquine 1

High-dose chloroquine is NOT recommended despite research showing efficacy 5, 6:

• While double-dose chloroquine (50 mg/kg) achieved 66-91% cure rates against pfcrt 76T parasites 5, current guidelines do not support this approach 1
• Standard treatment guidelines prioritize ACTs over experimental high-dose chloroquine regimens 1, 2

Pregnant women require special consideration 1:

• Quinine plus clindamycin is safe in all trimesters 1
• Monitor IV quinine carefully for hypoglycemia 3
• ACTs can be used when benefits outweigh risks 1

Drug availability determines choice 3:

• Selection should align with national malaria control policies 3
• Ensure adequate supply before initiating treatment programs 3